Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511849 · ClinicalTrials.gov registry record · Phase 1
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 4
- Study locations
NCT00511849: Completed Phase 1 study of Neoplasms, sponsored by Pfizer.
NCT00511849 is a Phase 1 study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 43 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00511849, a Phase 1 study of Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.
Conditions Studied
Interventions
- DRUG carboplatin + SU011248 (sunitinib) + paclitaxel
Study Locations (4)
Michigan
- Pfizer Investigational Site - Detroit
Pennsylvania
- Pfizer Investigational Site - Philadelphia
Texas
- Pfizer Investigational Site - Houston
Wisconsin
- Pfizer Investigational Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
What the finished NCT00511849 record still lists
NCT00511849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which carboplatin + SU011248 (sunitinib) + paclitaxel is the first listed.
NCT00511849 reports a single indexed study location in Michigan, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT00511849 about?
NCT00511849 is a clinical study titled "Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors". The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.
What is the current status of trial NCT00511849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2005-11. Estimated completion is 2009-02.
What conditions does trial NCT00511849 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00511849?
The interventions under investigation include: carboplatin + SU011248 (sunitinib) + paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00511849?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00511849 being conducted?
This trial has 4 study locations across Michigan, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00511849's enrollment target sits among peer trials
43 115th of 158 higher than 42 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia